AstraZeneca PLC (AZN)vsNephros Inc (NEPH)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
NEPH
Nephros Inc
$4.47
-1.11%
HEALTHCARE · Cap: $44.09M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 296039% more annual revenue ($61.37B vs $20.72M). AZN leads profitability with a 17.0% profit margin vs 8.4%. AZN trades at a lower P/E of 24.3x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
NEPH
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+12.6%
Fair Value
$4.62
Current Price
$4.47
$0.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 36.2% year-over-year
Earnings expanding 450.0% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Moderate valuation
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : NEPH
The primary concerns for NEPH are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while NEPH is a hypergrowth play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.56 — expect wider price swings.
NEPH is growing revenue faster at 36.2% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 58/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?